CCXI Summary

  1. NASDAQ
  2. >
  3. CCXI
TickerCCXI
DescriptionCHEMOCENTRYX INC
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Employees133
Next Earnings DateNovember 8th, 2022
IV11.894328%
IV Percentile2nd
IV Rank0.04%
IV Skew-10.006817
IV Skew Percentile12th
IV Skew SentimentBullish
Option Volume638
Volume2,891,876
Price$50.60
Previous Close$50.60
52-Week High$51.06
52-Week Low$13.11
50-Day Moving Avg.$28.70
200-Day Moving Avg.$25.10
10-Day Avg. Volume9,948,318
20-Day Avg. Volume3,978,599
30-Day Avg. Volume3,824,589
3-Month Avg. Volume2,080,386
EPS-$2.01
Outstanding Shares71,355,872
Market Capitalization$3,621,605,800
CurrencyUSD
UpdatedAugust 12th, 2022